Age and outcome after acute coronary syndromes without persistent ST- segment elevation

David Hasdai, David Holmes, Douglas A. Criger, Eric J. Topol, Robert M. Califf, Robert A. Harrington

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background: Although age is the most important variable associated with death among patients with persistent ST-segment elevation, its impact on outcome among patients without persistent ST-segment elevation remains unknown. Moreover, the impact of age on the efficacy of antiplatelet therapy with eptifibatide is unknown. Methods: We analyzed the impact of increased age on outcome (death or [re]infarction) among patients enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy), a prospective, randomized study comparing placebo versus eptifibatide therapy in acute coronary syndromes without persistent ST-segment elevation. The 9461 patients were divided into 10-year age groups: <50, 50-59, 60-69, 70-79, and ≥80. In addition, we examined whether age had an impact on the efficacy of eptifibatide therapy. Results: Eptifibatide improved outcome at 30 days (P = .04). There was no interaction among age and treatment (placebo vs eptifibatide) and adjusted outcome (P = .16 for death or [re]infarction at 30 days). Despite their worse clinical profile, older patients were less likely to undergo coronary angiography at 30 days: 936 (71%), 1489 (68%), 1969 (65%), 1357 (57%), and 193 (38%) in the respective age groups. Death or (re)infarction at 30 days occurred in 121 (9%), 255 (12%), 447 (15%), 460 (19%), and 134 (26%) in the respective age groups, and at 6 months in 149 (11%), 301 (14%), 547 (18%), 575 (24%), and 162 (32%). For a 10-year difference in age group, the adjusted odds for death or (re)infarction were greater by 33% within 30 days and by 34% within 6 months. These trends persisted for patients with or without myocardial infarction on presentation. Conclusions: Age did not significantly affect the efficacy of eptifibatide. Older age among patients with acute coronary syndromes was associated with worse baseline characteristics, fewer invasive procedures, and worse outcome.

Original languageEnglish (US)
Pages (from-to)858-866
Number of pages9
JournalAmerican Heart Journal
Volume139
Issue number5
DOIs
StatePublished - Jan 1 2000

Fingerprint

Acute Coronary Syndrome
Infarction
Age Groups
Placebos
Integrin beta3
Therapeutics
Platelet Glycoprotein GPIIb-IIIa Complex
Unstable Angina
eptifibatide
Coronary Angiography
Myocardial Infarction
Prospective Studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Age and outcome after acute coronary syndromes without persistent ST- segment elevation. / Hasdai, David; Holmes, David; Criger, Douglas A.; Topol, Eric J.; Califf, Robert M.; Harrington, Robert A.

In: American Heart Journal, Vol. 139, No. 5, 01.01.2000, p. 858-866.

Research output: Contribution to journalArticle

Hasdai, David ; Holmes, David ; Criger, Douglas A. ; Topol, Eric J. ; Califf, Robert M. ; Harrington, Robert A. / Age and outcome after acute coronary syndromes without persistent ST- segment elevation. In: American Heart Journal. 2000 ; Vol. 139, No. 5. pp. 858-866.
@article{afcb467ee0bf472eabd3795a75edcb0a,
title = "Age and outcome after acute coronary syndromes without persistent ST- segment elevation",
abstract = "Background: Although age is the most important variable associated with death among patients with persistent ST-segment elevation, its impact on outcome among patients without persistent ST-segment elevation remains unknown. Moreover, the impact of age on the efficacy of antiplatelet therapy with eptifibatide is unknown. Methods: We analyzed the impact of increased age on outcome (death or [re]infarction) among patients enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy), a prospective, randomized study comparing placebo versus eptifibatide therapy in acute coronary syndromes without persistent ST-segment elevation. The 9461 patients were divided into 10-year age groups: <50, 50-59, 60-69, 70-79, and ≥80. In addition, we examined whether age had an impact on the efficacy of eptifibatide therapy. Results: Eptifibatide improved outcome at 30 days (P = .04). There was no interaction among age and treatment (placebo vs eptifibatide) and adjusted outcome (P = .16 for death or [re]infarction at 30 days). Despite their worse clinical profile, older patients were less likely to undergo coronary angiography at 30 days: 936 (71{\%}), 1489 (68{\%}), 1969 (65{\%}), 1357 (57{\%}), and 193 (38{\%}) in the respective age groups. Death or (re)infarction at 30 days occurred in 121 (9{\%}), 255 (12{\%}), 447 (15{\%}), 460 (19{\%}), and 134 (26{\%}) in the respective age groups, and at 6 months in 149 (11{\%}), 301 (14{\%}), 547 (18{\%}), 575 (24{\%}), and 162 (32{\%}). For a 10-year difference in age group, the adjusted odds for death or (re)infarction were greater by 33{\%} within 30 days and by 34{\%} within 6 months. These trends persisted for patients with or without myocardial infarction on presentation. Conclusions: Age did not significantly affect the efficacy of eptifibatide. Older age among patients with acute coronary syndromes was associated with worse baseline characteristics, fewer invasive procedures, and worse outcome.",
author = "David Hasdai and David Holmes and Criger, {Douglas A.} and Topol, {Eric J.} and Califf, {Robert M.} and Harrington, {Robert A.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0002-8703(00)90018-8",
language = "English (US)",
volume = "139",
pages = "858--866",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Age and outcome after acute coronary syndromes without persistent ST- segment elevation

AU - Hasdai, David

AU - Holmes, David

AU - Criger, Douglas A.

AU - Topol, Eric J.

AU - Califf, Robert M.

AU - Harrington, Robert A.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: Although age is the most important variable associated with death among patients with persistent ST-segment elevation, its impact on outcome among patients without persistent ST-segment elevation remains unknown. Moreover, the impact of age on the efficacy of antiplatelet therapy with eptifibatide is unknown. Methods: We analyzed the impact of increased age on outcome (death or [re]infarction) among patients enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy), a prospective, randomized study comparing placebo versus eptifibatide therapy in acute coronary syndromes without persistent ST-segment elevation. The 9461 patients were divided into 10-year age groups: <50, 50-59, 60-69, 70-79, and ≥80. In addition, we examined whether age had an impact on the efficacy of eptifibatide therapy. Results: Eptifibatide improved outcome at 30 days (P = .04). There was no interaction among age and treatment (placebo vs eptifibatide) and adjusted outcome (P = .16 for death or [re]infarction at 30 days). Despite their worse clinical profile, older patients were less likely to undergo coronary angiography at 30 days: 936 (71%), 1489 (68%), 1969 (65%), 1357 (57%), and 193 (38%) in the respective age groups. Death or (re)infarction at 30 days occurred in 121 (9%), 255 (12%), 447 (15%), 460 (19%), and 134 (26%) in the respective age groups, and at 6 months in 149 (11%), 301 (14%), 547 (18%), 575 (24%), and 162 (32%). For a 10-year difference in age group, the adjusted odds for death or (re)infarction were greater by 33% within 30 days and by 34% within 6 months. These trends persisted for patients with or without myocardial infarction on presentation. Conclusions: Age did not significantly affect the efficacy of eptifibatide. Older age among patients with acute coronary syndromes was associated with worse baseline characteristics, fewer invasive procedures, and worse outcome.

AB - Background: Although age is the most important variable associated with death among patients with persistent ST-segment elevation, its impact on outcome among patients without persistent ST-segment elevation remains unknown. Moreover, the impact of age on the efficacy of antiplatelet therapy with eptifibatide is unknown. Methods: We analyzed the impact of increased age on outcome (death or [re]infarction) among patients enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy), a prospective, randomized study comparing placebo versus eptifibatide therapy in acute coronary syndromes without persistent ST-segment elevation. The 9461 patients were divided into 10-year age groups: <50, 50-59, 60-69, 70-79, and ≥80. In addition, we examined whether age had an impact on the efficacy of eptifibatide therapy. Results: Eptifibatide improved outcome at 30 days (P = .04). There was no interaction among age and treatment (placebo vs eptifibatide) and adjusted outcome (P = .16 for death or [re]infarction at 30 days). Despite their worse clinical profile, older patients were less likely to undergo coronary angiography at 30 days: 936 (71%), 1489 (68%), 1969 (65%), 1357 (57%), and 193 (38%) in the respective age groups. Death or (re)infarction at 30 days occurred in 121 (9%), 255 (12%), 447 (15%), 460 (19%), and 134 (26%) in the respective age groups, and at 6 months in 149 (11%), 301 (14%), 547 (18%), 575 (24%), and 162 (32%). For a 10-year difference in age group, the adjusted odds for death or (re)infarction were greater by 33% within 30 days and by 34% within 6 months. These trends persisted for patients with or without myocardial infarction on presentation. Conclusions: Age did not significantly affect the efficacy of eptifibatide. Older age among patients with acute coronary syndromes was associated with worse baseline characteristics, fewer invasive procedures, and worse outcome.

UR - http://www.scopus.com/inward/record.url?scp=0034027115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034027115&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(00)90018-8

DO - 10.1016/S0002-8703(00)90018-8

M3 - Article

C2 - 10783220

AN - SCOPUS:0034027115

VL - 139

SP - 858

EP - 866

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -